Heartflow Sues Elucid Over Patent Infringement Claims
The company alleges that Elucid misappropriated trade secrets and infringed upon its cardiovascular technology patents.
Updated on Oct. 26, 2026 in Heart Disease
Live Poll
Should courts favor strict patent enforcement when rival companies hire competitors' former employees?
Heartflow has filed a patent infringement and trade secret misappropriation lawsuit against Elucid in the U.S. District Court for the District of Massachusetts. The complaint claims Elucid hired 11 former Heartflow employees to gain access to confidential product designs and customer lists.
Why it matters
This litigation highlights the intense legal competition surrounding the development of CT-derived fractional flow reserve products. The outcome may impact how companies protect proprietary cardiac imaging technologies as the market for these diagnostic tools expands.
The lawsuit alleges infringement of four specific U.S. patents, including numbers 9,754,082 and 10,010,255. While Elucid has received FDA marketing authorization for its FFR-IQ product, the legal dispute over the underlying development remains ongoing.
The players
Heartflow
Heartflow is a company that specializes in heart disease diagnostic technology, specifically through the development of CT-derived fractional flow reserve products.
Elucid
Elucid is a medical technology company that recently received FDA marketing authorization for its FFR-IQ diagnostic product.
Cleerly
Cleerly is a digital healthcare company that was the subject of a previous patent lawsuit filed by Heartflow in Texas.
The details
Heartflow alleges that Elucid utilized former staff to secure proprietary information related to its fractional flow reserve technology. This filing follows a similar legal strategy previously employed by Heartflow against Cleerly in a separate Texas federal court.
Timeline
Heartflow filed the legal complaint against Elucid on October 22, 2026.
Health Landscape
The current litigation against Elucid follows a pattern of patent enforcement previously established by Heartflow's lawsuit against Cleerly. Such disputes underscore the high stakes for companies seeking to dominate the proprietary landscape of cardiac imaging diagnostics.
This lawsuit may impact the availability or development timelines of new diagnostic imaging technologies for patients. Future clinical access to these heart-monitoring tools remains dependent on how these companies resolve their intellectual property conflicts.
The takeaway
Legal battles over trade secrets in medical technology can lead to significant delays in market availability for new diagnostic products. Industry participants should monitor these court proceedings as they often shape the competitive landscape for non-invasive heart assessment tools.
Further reading
Learn more about the latest innovations and challenges in Heart Disease.
Source note: This article includes information reported by AuntMinnie.
Live Poll
Should courts favor strict patent enforcement when rival companies hire competitors' former employees?
